Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster
New Oncolines case study presented at ENA 2024 conference in Barcelona
Oncolines will present three posters at the EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics conference that will be held in Barcelona (Spain) from October […]
Oncolines launches assay for long COVID and cancer immunotherapy target IDO2
The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 2 (IDO2) is a potential therapeutic target for long COVID and cancer immunotherapy. IDO2 has 44% amino acid identity […]
Oncolines offers cell toxicity as an alternative readout for 102 cancer cell panel profiling studies
Oncolines® profiling is the parallel testing of compounds, either small molecules or biologics, on a large panel of human cancer cell lines. We use […]
New insights into the targeting of amino acid-metabolizing enzymes for cancer immunotherapy
Over the recent decades, cancer immunotherapy has emerged as a revolutionary approach to reinvigorate host anti-tumor immunity. However, while immune checkpoint inhibitors have proven […]
Premium Benefits of Oncolines Precision Medicine Services: Cell-Based Assays, Drug Combinations, High-Throughput Screening